CoVPN 3501/BLAZE-2: Eli Lilly’s Bamlanivimab (LY-CoV555) Antibody

Read the latest news releases:

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
• Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19

BLAZE-2 tested monoclonal antibodies. The study enrolled staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions were: 

• Does the antibody prevent the acquisition of SARS-CoV-2?
• Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?

The study was conducted in the United States and enrolled 196 participants. 

Monoclonal antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. Monoclonal antibodies were developed in a lab by the pharmaceutical company Eli Lilly. Monoclonal antibodies cannot give you SARS-CoV-2, nor will they make you sick with COVID-19. 

Visit ClinicalTrials.gov - NCT04497987 for additional details about the Eli Lilly monoclonal antibody clinical study to prevent COVID-19.